CN105456575A - Traditional Chinese medicine preparation for treating fatty liver - Google Patents

Traditional Chinese medicine preparation for treating fatty liver Download PDF

Info

Publication number
CN105456575A
CN105456575A CN201511033759.0A CN201511033759A CN105456575A CN 105456575 A CN105456575 A CN 105456575A CN 201511033759 A CN201511033759 A CN 201511033759A CN 105456575 A CN105456575 A CN 105456575A
Authority
CN
China
Prior art keywords
chinese medicine
medicine preparation
radix
liver
crude drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201511033759.0A
Other languages
Chinese (zh)
Inventor
李常青
李小翚
黄玉影
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou University of Chinese Medicine
Original Assignee
Guangzhou University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou University of Chinese Medicine filed Critical Guangzhou University of Chinese Medicine
Priority to CN201511033759.0A priority Critical patent/CN105456575A/en
Publication of CN105456575A publication Critical patent/CN105456575A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a traditional Chinese medicine preparation for treating the fatty liver. The traditional Chinese medicine preparation is prepared from effective ingredients and medically acceptable auxiliary materials. The effective ingredients comprise, by weight, 5%-30% of codonopsis pilosula, 5%-30% of rhizoma alismatis, 5%-30% of the root of kudzu vine, 4%-10% of panax notoginseng, 5%-25% of the root of red-rooted salvia, 5%-15% of pollen typhae, 5%-30% of prepared fleece flower roots, 5%-30% of serrate rabdosia herb and 5%-30% of serrate rabdosia herbs. Codonopsis pilosula in the traditional Chinese medicine preparation can invigorate the spleen to eliminate dampness and serves as a monarch drug. Rhizoma alismatis, the root of kudzu vine and serrate rabdosia herb can resolve dampness and relieve internal heat of fever, and panax notoginseng, the root of red-rooted salvia and pollen typhae can promote blood circulation to remove blood stasis and serve as a ministerial drug. Prepared fleece flower roots can tonify the kidney and nourish the lever, lychee seeds can promote the circulation of qi and remove stasis and serves as an adjuvant drug, the nine kinds of medicine are used together, the functions of invigorating the spleen to eliminate dampness and invigorating the circulation of blood and tonifying the kidney are achieved together, then liver lipidosis is restrained, liver fat is promoted to be degraded, liver lipidosis is reduced, and the remarkable curative effect on the fatty liver is achieved.

Description

A kind of Chinese medicine preparation for the treatment of fatty liver
Technical field
The invention belongs to technical field of Chinese medicines.More specifically, a kind of Chinese medicine preparation for the treatment of fatty liver is related to.
Background technology
Fatty liver refers to the pathological changes due to overheap fatty in the hepatocyte that a variety of causes causes.The bad life style of increase and hypomotility taken in by higher fatty acid, high caloric diet, pathogenesis of fatty liver rate is caused constantly to increase and gradually become younger, increase the pathogenetic risk of the disease such as cardiovascular disease, diabetes, even develop into the End-stage liver disease such as liver cirrhosis, hepatocarcinoma, fatty liver is the second largest hepatopathy being only second to viral hepatitis, has become the important diseases of harm humans health.
Keeping fit through sport and keeping on a diet is the main prevention and controls of current fatty liver, but patient compliance is not high, poor effect.Western medicine there is no generally acknowledged effective pharmaceutical preparation at present.Although lipid lowerers, fat euglycemic agent and antioxidant can be used for the treatment of fatty liver, the improvement result of these medicines to Patients with Fatty Liver Serum enzyme spectrum exception and liver histological pathological change is limited, and clinical efficacy is not good.
And Chinese medicine fatty liver is by improving lipid metabolism, anti-oxidation stress, improving insulin resistant, suppress er stress, promoting that the effects such as liver degradation of lipid reach disease therapy object, have the action character of Mutiple Targets, and toxic and side effects are little.In recent years, Chinese medicine plays an increasingly important role in the treatment of fatty liver, is current study hotspot.Chinese medicine fatty liver mainly contains medicine typing treatment, specific prescription and medication, Chinese patent drugs for treatment etc.Wherein, in the long-term clinical practice of Chinese medicine fatty liver, many doctors have explored the medicine of some effective empirical formulas and multiple dosage form, demonstrate good therapeutic effect, such as notification number is that the patent of invention of CN104689218A discloses " a kind of Chinese medicine composition for the treatment of fatty liver ", wherein said Chinese medicine has the effect adopting and have wet diuretic, invigorating the spleen and regulating the stomach, mind tranquilizing and the heart calming, has good curative effect to fatty liver.
But curative effect still needs further to be promoted, and in the face of extremely abundant natural resources of Chinese medicinal materials, constantly explores new Chinese medicine preparation, to the application development of Chinese crude drug and the treatment of Fatty Liver Disease, all have great importance.
Summary of the invention
The technical problem to be solved in the present invention is the deficiency overcoming existing fatty liver medicine, a kind of Chinese medicine preparation for the treatment of fatty liver is newly provided, said preparation can invigorating the spleen for eliminating dampness, blood-activating kidney-tonifying, suppress liver lipids deposition, promote liver fat acid decomposition, to fatty liver, there is significant curative effect.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
A kind of Chinese medicine preparation for the treatment of fatty liver, said preparation is made up of active ingredient and the acceptable adjuvant of medical science, and wherein said active ingredient is made up of the crude drug of following percentage by weight: Radix Codonopsis 5 ~ 30%, Rhizoma Alismatis 5 ~ 30%, Radix Puerariae 5 ~ 30%, Radix Notoginseng 4 ~ 10%, Radix Salviae Miltiorrhizae 5 ~ 25%, Pollen Typhae 5 ~ 15%, Radix Polygoni Multiflori Preparata 5 ~ 30%, Herba Rabdosiae Lophanthoidis 5 ~ 30%, Semen Litchi 5 ~ 30%.
Above-mentioned 9 tastes share, and gather effect of invigorating the spleen for eliminating dampness, blood-activating kidney-tonifying altogether, and then promote liver lipids degraded, suppress liver lipids deposition, reach the object for the treatment of fatty liver.
Further preferably, the active ingredient in above-mentioned Chinese medicine preparation is made up of the crude drug of following percentage by weight: Radix Codonopsis 10%, Rhizoma Alismatis 5%, Radix Puerariae 15%, Radix Notoginseng 5%, Radix Salviae Miltiorrhizae 15%, Pollen Typhae 5%, Radix Polygoni Multiflori Preparata 15%, Herba Rabdosiae Lophanthoidis 15%, Semen Litchi 15%.
In addition, preferably, the preparation method of the active ingredient in above-mentioned Chinese medicine preparation comprises the steps:
S1. by crude drug cutting, pulverize, add the ethanol of 8 ~ 12 times 60%, homogenate, centrifugal, obtain centrifugal liquid and centrifugal slag;
S2. the centrifugal liquid of step S1 filtered, then reverse osmosis concentration obtains concentrated solution, then reclaims ethanol and vacuum concentration, obtains extractum;
S3. mixed homogeneously with water by the centrifugal slag of step S1, stir furnishing slurry, homogenate, centrifugally removes slag, and after filtering, reverse osmosis concentration obtains concentrated solution to centrifugal liquid;
S4. by the extractum of step S2 with the concentrated solution of step S3 is merged, be uniformly mixed, through ceramic membrane filter core filtering, spraying dry, to obtain final product.
Wherein, preferably, described in step S2, filtration refers to successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element.
Preferably, described in step S2, the degree of reverse osmosis concentration is: be concentrated into the concentration be equivalent to containing 0.6 ~ 1.0kg crude drug in often liter of concentrated solution.
Preferably, described in step S2, the degree of vacuum concentration is: be concentrated into the concentration be equivalent to containing 1.4 ~ 1.8kg crude drug in often liter of extractum.
Preferably, the amount of water described in step S3 is 10 ~ 20 times of crude drug total amount.
Preferably, described in step S3, filtration refers to successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element.
Preferably, described in step S3, the degree of reverse osmosis concentration is: be concentrated into the concentration be equivalent to containing 1.8 ~ 3.6kg crude drug in often liter of concentrated solution.
In addition, preferably, said preparation can be the oral formulations of various routine.
More preferably, said preparation can be granule, tablet or capsule etc.
In the Chinese medicine preparation for the treatment of fatty liver of the present invention, Radix Codonopsis invigorating the spleen for eliminating dampness is monarch drug; Rhizoma Alismatis, Radix Puerariae, Herba Rabdosiae Lophanthoidis removing dampness removing toxic substances, Radix Notoginseng, Radix Salviae Miltiorrhizae, Pollen Typhae blood circulation promoting and blood stasis dispelling are ministerial drug; Radix Polygoni Multiflori Preparata the kidney invigorating nourishing the liver, Semen Litchi promoting QI to circulate and dispersing the agglomeration of the pathogens is adjuvant drug; Above-mentioned nine tastes share, and gather the merit of invigorating the spleen for eliminating dampness, blood-activating kidney-tonifying altogether, and then suppress liver lipids deposition, promote fat acid decomposition, reach the object for the treatment of fatty liver.
The present invention has following beneficial effect:
The invention provides a kind of Chinese medicine preparation for the treatment of fatty liver, said preparation can invigorating the spleen for eliminating dampness, blood-activating kidney-tonifying, suppress liver lipids deposition, promote liver fat acid decomposition, to fatty liver, there is significant curative effect.
This Chinese medicine preparation feeds to high lipid food the fatty liver model of rats increasing the foundation of fat liquor gavage good therapeutical effect, obviously can promote that liver lipids is degraded, alleviate liver lipids deposition, its mechanism of action and regulating lipid metabolism, reduce FFA level and anti-oxidation stress relevant.
In Chinese medicine preparation of the present invention, Radix Codonopsis invigorating the spleen for eliminating dampness is monarch drug; Rhizoma Alismatis, Radix Puerariae, Herba Rabdosiae Lophanthoidis removing dampness removing toxic substances, Radix Notoginseng, Radix Salviae Miltiorrhizae, Pollen Typhae blood circulation promoting and blood stasis dispelling are ministerial drug; Radix Polygoni Multiflori Preparata the kidney invigorating nourishing the liver, Semen Litchi promoting QI to circulate and dispersing the agglomeration of the pathogens is adjuvant drug; Above-mentioned nine tastes share, and gather the merit of invigorating the spleen for eliminating dampness, blood-activating kidney-tonifying altogether, and then suppress liver lipids deposition, promote fat acid decomposition, reach the object for the treatment of fatty liver.
Accompanying drawing explanation
Fig. 1 is that each group of rat liver tissue pathological state compares (HE dyes, × 250).
Fig. 2 is that each group of rat liver tissue pathological change is compared (oil red O stain, × 250).
Detailed description of the invention
Further illustrate the present invention below in conjunction with Figure of description and specific embodiment, but embodiment does not limit in any form to the present invention.Unless stated otherwise, the present invention adopts reagent, method and apparatus are the art conventional reagent, method and apparatus.
Unless stated otherwise, following examples agents useful for same and material are commercial.
Statistical procedures method in following examples: measurement data is with mean ± standard deviation represent, adopt SPSS10.0 to process each experimental group data, the analysis of many Sets of Measurement Datas adopts OnewayANOVA, and multiple comparisons adopts LSD, represents that difference has significant with P<0.05.
Embodiment 1 Chinese medicine preparation
1, prescription:
Radix Codonopsis 1920g, Rhizoma Alismatis 320g, Radix Puerariae 320g, Radix Notoginseng 640g, Radix Salviae Miltiorrhizae 640g, Pollen Typhae 320g, Radix Polygoni Multiflori Preparata 960g, Herba Rabdosiae Lophanthoidis 640g, Semen Litchi 640g.
(this prescription is made up of the crude drug of following mass percent: Radix Codonopsis 30%, Rhizoma Alismatis 5%, Radix Puerariae 5%, Radix Notoginseng 10%, Radix Salviae Miltiorrhizae 10%, Pollen Typhae 5%, Radix Polygoni Multiflori Preparata 15%, Herba Rabdosiae Lophanthoidis 10%, Semen Litchi 10%).
2, preparation method:
(1) by the cutting of prescription weighting raw materials, pulverize, add the ethanol of 12 times 60%, homogenate, centrifugal, obtain centrifugal liquid and centrifugal slag;
(2) centrifugal liquid step (1) obtained is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, then first the reverse osmosis concentrated cocnentration factor that is reduced to was 1: 1 (being equivalent in often liter of concentrated solution containing 1kg crude drug), then reclaimed ethanol and vacuum concentration becomes cocnentration factor to be the extractum of 2: 1 (being equivalent in often liter of extractum containing 2kg crude drug);
(3) the centrifugal slag that step (1) is obtained is mixed homogeneously with the water of the total amount 10 times of described crude drug, stirring furnishing is starched, homogenate, the centrifugal b that removes slag, centrifugal liquid is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, and reverse osmosis concentration obtains the concentrated solution that cocnentration factor was 3: 1 (being equivalent in often liter of concentrated solution containing 3kg crude drug);
(4) extractum obtained for step (2) is merged with the concentrated solution that step (3) is obtained, be uniformly mixed, through ceramic membrane filter core filtering, spraying dry, obtained active ingredient;
(5) by active ingredient with 15% maltodextrin slurry for binding agent, spray granulation, adds the magnesium stearate of granule total amount 0.5%, mix homogeneously, tabletting, obtains tablet, 0.45g/ sheet.
3, instructions of taking and dosage:
Warm water takes, every day 3 times, each 4.
Embodiment 2 Chinese medicine preparation
1, prescription:
Radix Codonopsis 640g, Rhizoma Alismatis 320g, Radix Puerariae 960g, Radix Notoginseng 320g, Radix Salviae Miltiorrhizae 960g, Pollen Typhae 320g, Radix Polygoni Multiflori Preparata 960g, Herba Rabdosiae Lophanthoidis 960g, Semen Litchi 960g.
(this prescription is made up of the crude drug of following mass percent: Radix Codonopsis 10%, Rhizoma Alismatis 5%, Radix Puerariae 15%, Radix Notoginseng 5%, Radix Salviae Miltiorrhizae 15%, Pollen Typhae 5%, Radix Polygoni Multiflori Preparata 15%, Herba Rabdosiae Lophanthoidis 15%, Semen Litchi 15%).
2, preparation method:
(1) by the cutting of prescription weighting raw materials, pulverize, add the ethanol of 8 times 60%, homogenate, centrifugal, obtain centrifugal liquid and centrifugal slag;
(2) centrifugal liquid step (1) obtained is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, then first the reverse osmosis concentrated cocnentration factor that is reduced to was 1: 1 (being equivalent in often liter of concentrated solution containing 1kg crude drug), then reclaimed ethanol and vacuum concentration becomes cocnentration factor to be the extractum of 1.6: 1 (being equivalent in often liter of extractum containing 1.6kg crude drug);
(3) the centrifugal slag that step (1) is obtained is mixed homogeneously with the water of the total amount 15 times of described crude drug, stirring furnishing is starched, homogenate, the centrifugal b that removes slag, centrifugal liquid is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, and reverse osmosis concentration obtains the concentrated solution that cocnentration factor was 3: 1 (being equivalent in often liter of concentrated solution containing 3kg crude drug);
(4) extractum obtained for step (2) is merged with the concentrated solution that step (3) is obtained, be uniformly mixed, through ceramic membrane filter core filtering, spraying dry, obtained active ingredient;
(5) by active ingredient with 15% maltodextrin slurry for binding agent, spray granulation, quantitative separating, obtains granular preparation, 3.5g/ bag.
3, instructions of taking and dosage:
Warm water takes, every day 1 time, each 2 bags.
Embodiment 3 Chinese medicine preparation
1, prescription:
Radix Codonopsis 1280g, Rhizoma Alismatis 1280g, Radix Puerariae 640g, Radix Notoginseng 640g, Radix Salviae Miltiorrhizae 640g, Pollen Typhae 640g, Radix Polygoni Multiflori Preparata 640g, Herba Rabdosiae Lophanthoidis 320g, Semen Litchi 320g.
(this prescription is made up of the crude drug of following mass percent: Radix Codonopsis 20%, Rhizoma Alismatis 20%, Radix Puerariae 10%, Radix Notoginseng 10%, Radix Salviae Miltiorrhizae 10%, Pollen Typhae 10%, Radix Polygoni Multiflori Preparata 10%, Herba Rabdosiae Lophanthoidis 5%, Semen Litchi 5%).
(1) by the cutting of prescription weighting raw materials, pulverize, add the ethanol of 10 times 60%, homogenate, centrifugal, obtain centrifugal liquid and centrifugal slag;
(2) centrifugal liquid step (1) obtained is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, then first the reverse osmosis concentrated cocnentration factor that is reduced to was 1: 1 (being equivalent in often liter of concentrated solution containing 1kg crude drug), then reclaimed ethanol and vacuum concentration becomes cocnentration factor to be the extractum of 1.6: 1 (being equivalent in often liter of extractum containing 1.6kg crude drug);
(3) the centrifugal slag that step (1) is obtained is mixed homogeneously with the water of the total amount 15 times of described crude drug, stirring furnishing is starched, homogenate, the centrifugal b that removes slag, centrifugal liquid is successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element, and reverse osmosis concentration obtains the concentrated solution that cocnentration factor was 3: 1 (being equivalent in often liter of concentrated solution containing 3kg crude drug);
(4) extractum obtained for step (2) is merged with the concentrated solution that step (3) is obtained, be uniformly mixed, through ceramic membrane filter core filtering, spraying dry, obtained active ingredient;
(5) by active ingredient with 15% maltodextrin slurry for binding agent, spray granulation, adds the magnesium stearate of granule total amount 0.5%, mix homogeneously, filled capsules, obtains capsule, 0.30g/ grain.
3, instructions of taking and dosage:
Warm water takes, every day 3 times, each 6.
The anti-fatty liver drug effect test of embodiment 4 Chinese medicine preparation
1, experiment material
(1) for reagent thing
1) the confession reagent thing for the treatment of group 1: the active ingredient that Example 1 obtains, adds and dissolve with distilled water, be made into the medicinal liquid that active ingredient concentration is 0.4Kg/L.
2) the confession reagent thing for the treatment of group 2: the active ingredient that Example 2 obtains, adds and dissolve with distilled water, be made into the medicinal liquid that active ingredient concentration is 0.4Kg/L.
3) the confession reagent thing for the treatment of group 3: the active ingredient that Example 3 obtains, adds and dissolve with distilled water, be made into the medicinal liquid that active ingredient concentration is 0.4Kg/L.
(2) animal, feedstuff and high fat liquor
SPF level SD rat 48, male and female half and half, weight (200 ± 20) g, is provided by Guangdong Medical Lab Animal Center, credit number SCXK (Guangdong) 2013-0002.High lipid food (mass fraction): 73.8% normal feedstuff, 10% Adeps Sus domestica, 10% yolk powder, 1% cholesterol, 5% sucrose, 0.2% cholate, thered is provided by Guangdong Medical Lab Animal Center, credit number SCXK (Guangdong) 2013-0002.The self-control of high fat liquor, every 100mL is appropriate containing Adeps Sus domestica 20g, Oleum Arachidis hypogaeae semen 30g, cholesterol 15g, Fel Sus domestica salt 3g, tween 80 5mL, propylene glycol 5mL, distilled water.Basis Mus material: SPF is grade packaged, is provided, simvastatin by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center, Qilu Pharmaceutical Co., Ltd.'s (lot number: 3040011NV).
(3) main agents and instrument
140761), cholesterol test box (lot number: 141151), glutamate pyruvate transaminase testing cassete (lot number: 140611) and glutamic oxaloacetic transaminase, GOT testing cassete (lot number: 140561) produce by Zhong Shengbeikong bio tech ltd triglyceride testing cassete (lot number:; HDL-C testing cassete (lot number: 806RCL) and low-density lipoprotein cholesterol testing cassete (lot number: 810RLK) are produced by Japanese hydrops Co., Ltd.; Triglyceride testing cassete is (for measuring liver lipid, lot number: 20150423), cholesterol test box (for measuring liver lipid, lot number: 20150325), free fatty testing cassete (lot number: 20150326), total number born testing cassete (lot number: 20150407), malonaldehyde testing cassete (lot number: 20150324) by Nanjing build up Bioengineering Research Institute produce; 3202090), cholesterol (lot number: 2102013) produced by Huankai Microbes Tech Co., Ltd., Guangdong Fel Sus domestica salt (lot number:; Tween 80, propylene glycol are food stage, are purchased from Guangzhou eastward fight Hua Bo Instrument Ltd.; OlympusAU5421 automatic clinical chemistry analyzer (Japanese OLYMPUS Optical Co., Ltd); XDS-2 inverted microscope (GuangZhou, China optical instrument factory).
2, modeling and medication
48 SPF level SD rat feedings are in Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center (credit number SYXK (Guangdong) 2013-0001), adaptability is divided into 6 groups at random according to body weight after raising 7d: normal group, model group, treatment group 1-3 (4.0g/kg, suitable clinical medicine dose after converting) and simvastatin group (2.0mg/kg, suitable clinical medicine dose after converting), often organize 8, male and female half and half, sub-cage rearing, weighs weekly once.Normal rats adopts normal feedstuff to feed, while modeling group and each administration group rat are fed with high lipid food, the high fat liquor of gavage respective volume in the following order: the 1st week 2.5mL/kg, the 2nd week 5.0mL/kg, the 3rd week 7.5mL/kg, 4 ~ 8 weeks 10mL/kg, take 50mL/kg as the upper limit, modeling 8 weeks altogether; Within 9th week, start whole rat and give normal feedstuff nursing, the equal gastric infusion of each administration group rat, normal group and model group rats gavage every day equal-volume distilled water, administration the 4th weekend, water 16h is can't help in fasting, and with 20mg/L pentobarbital sodium with 2mL/kg volume intraperitoneal injection of anesthesia, ventral aorta is taken a blood sample, cut rapidly that hepatic tissue is put in cryopreservation tube, to be placed in liquid nitrogen for subsequent use, cutting right lobe of liver tissue, to be put in volume fraction be fixing, censorship in the neutral formalin of 10%.
3, the observation of rat ordinary circumstance
The clean and tidy gloss of normal rats hair, action are flexibly, diet drinking-water is normal, Excreta is normal, continued weight steady growth.Modeling group Hair of Rats slightly owes clean and tidy gloss, compared with not liking activity, diet drinking-water is normal, Excreta is greasy, body weight increases more than normal group.Female Mus is fewer and more active than male Mus diet amount of drinking water.Change feedstuff and after removing high fat liquor gavage during administration, model group and each administration group Hair of Rats are comparatively clean and tidy during modeling, activity slightly increases, each administration group rat Excreta compared with normal.
4, blood fat, blood glucose and Liver function grade
(1) 1h is left standstill after blood sampling, the centrifugal 10min of 3000r/min, automatic clinical chemistry analyzer detects triglyceride (TG), cholesterol (CHOL), HDL-C (HDL-C), low-density lipoprotein cholesterol (LDL-C) and glutamate pyruvate transaminase (ALT) content in serum.
Adopt colorimetric method for determining serum free fatty acid (FFA) assay.
(2) rat fat, serum FFA comparision contents is respectively organized
Table 1 result shows: compare with normal group, model group rats serum triglycerides (TG), T-CHOL (CHOL), LDL-C, FFA level all obviously raise (P<0.05); Compare with model group, treatment group 1, treatment group 2, treatment group 3 serum TG, CHOL, LDL-C, FFA level all significantly reduce (P<0.05,0.01), and treatment group 2 serum TG and FFA level all remarkable in simvastatin group (P<0.05).
Table 1 respectively organize rat fat, serum FFA comparison ( n=8)
Note: compare with normal group, *p<0.05, *p<0.01; Compare with model group, △p<0.05, △ △p<0.01; Compare with simvastatin group, ★p<0.05.
(3) each group Liver Function compares
Table 2 result shows: compare with normal group, model group rats ALT content does not have significant difference (P>0.05), illustrates that modeling rat does not have hepatic injury to occur.Compare with model group, treatment group 1, treatment group 2, treatment group 3 groups of Serum ALT content are all without significant difference (P>0.05).
Table 2 each group Liver Function compares ( n=8)
5, hepatic tissue index determining
(1) liver lipid content measures: take 0.2g hepatic tissue, add the dehydrated alcohol (analytical pure) of 9 times of volumes, make 100g/L liver homogenate with electric homogenizer, use GPO-peroxidase conjugate (GPO-PAP) method, cholesterol oxidase-peroxidase conjugate (COD-PAP) method to measure triglyceride (TG) content in 100g/L liver homogenate and cholesterol (CHOL) content respectively according to test kit description.
(2) hepatic tissue total number born (SOD), malonaldehyde (MDA) assay: take 0.2g hepatic tissue, add the normal saline of 9 times of volumes, make 100g/L liver homogenate with electric homogenizer, use SOD, MDA content in water solublity tetrazole (WST-1) method, thiobarbituricacidα-(TBA) method mensuration 100g/L liver homogenate respectively according to test kit description.
(3) each group rats'liver lipid and liver oxidizes stress degree compare
Table 3 result shows: compare with normal group, in model group rats hepatic tissue, triglyceride (TG), T-CHOL (CHOL) and MDA content all obviously raise (P<0.05,0.01), and SOD content significantly reduces (P<0.05); Compare with model group, TG, CHOL and MDA content in treatment group 1, treatment group 2, treatment group 3 liver tissues of rats all significantly reduces (P<0.05,0.01), and SOD content significantly raises (P<0.05), with simvastatin group comparing difference there are no significant meaning (P>0.05).
Table 3 respectively group rats'liver lipid and oxidative stress degree comparison ( n=8)
Note: compare with normal group, *p<0.05, *p<0.01; Compare with model group, △p<0.05, △ △p<0.01.
7, liver histopathology
(1) get volume fraction be 10% neutral formalin fix after hepatic tissue, routine paraffin wax embedding, section and HE dyeing, light Microscopic observation hepatic tissue pathology change; Get freezing hepatic tissue section, oil red O stain, light Microscopic observation liver fat lesion situation.
(2) each group liver tissues of rats section HE dyeing and oil red O stain pathological observation result are as shown in figure 1 and 2.
Fig. 1 result shows: normal rats hepatocyte size, plesiomorphism, nucleus are positioned at cell central authorities; In model group rats hepatocyte, diffusivity steatosis is obvious, and cell size is uneven, and steatosis makes nuclear translocation; Each administration group steatosis significantly reduces, and cellular morphology is even.
Fig. 2 result shows: normal rats hepatocyte has no obvious fat vacuole and occurs; In model group rats hepatocyte, fat vacuole is widely distributed, illustrates in cell to there is a large amount of lipid; In each administration group hepatocyte, fat vacuole all significantly reduces, and obviously can improve the pathological state of liver lipidosis.
In sum, this Chinese medicine preparation feeds to high lipid food the fatty liver model of rats increasing the foundation of fat liquor gavage good therapeutical effect, obviously can promote that liver lipids is degraded, alleviate liver lipids deposition, especially best with the therapeutic effect for the treatment of group 2, the Chinese medicinal components dosage ratio of prompting embodiment 2 is better, its mechanism of action and regulating lipid metabolism, reduce FFA level and anti-oxidation stress relevant.

Claims (10)

1. treat the Chinese medicine preparation of fatty liver for one kind, it is characterized in that, be made up of active ingredient and the acceptable adjuvant of medical science, wherein said active ingredient is made up of the crude drug of following percentage by weight: Radix Codonopsis 5 ~ 30%, Rhizoma Alismatis 5 ~ 30%, Radix Puerariae 5 ~ 30%, Radix Notoginseng 4 ~ 10%, Radix Salviae Miltiorrhizae 5 ~ 25%, Pollen Typhae 5 ~ 15%, Radix Polygoni Multiflori Preparata 5 ~ 30%, Herba Rabdosiae Lophanthoidis 5 ~ 30%, Semen Litchi 5 ~ 30%.
2. Chinese medicine preparation according to claim 1, it is characterized in that, described active ingredient is made up of the crude drug of following percentage by weight: Radix Codonopsis 10%, Rhizoma Alismatis 5%, Radix Puerariae 15%, Radix Notoginseng 5%, Radix Salviae Miltiorrhizae 15%, Pollen Typhae 5%, Radix Polygoni Multiflori Preparata 15%, Herba Rabdosiae Lophanthoidis 15%, Semen Litchi 15%.
3. Chinese medicine preparation according to claim 1, is characterized in that, the preparation method of described active ingredient comprises the steps:
S1. by crude drug cutting, pulverize, add the ethanol of 8 ~ 12 times 60%, homogenate, centrifugal, obtain centrifugal liquid and centrifugal slag;
S2. the centrifugal liquid of step S1 filtered, then reverse osmosis concentration obtains concentrated solution, then reclaims ethanol and vacuum concentration, obtains extractum;
S3. mixed homogeneously with water by the centrifugal slag of step S1, stir furnishing slurry, homogenate, centrifugally removes slag, and after filtering, reverse osmosis concentration obtains concentrated solution to centrifugal liquid;
S4. by the extractum of step S2 with the concentrated solution of step S3 is merged, be uniformly mixed, through ceramic membrane filter core filtering, spraying dry, to obtain final product.
4. Chinese medicine preparation according to claim 3, is characterized in that, filters and refer to successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element described in step S2.
5. Chinese medicine preparation according to claim 3, is characterized in that, described in step S2, the degree of reverse osmosis concentration is: be concentrated into the concentration be equivalent to containing 0.6 ~ 1.0kg crude drug in often liter of concentrated solution.
6. Chinese medicine preparation according to claim 3, is characterized in that, described in step S2, the degree of vacuum concentration is: be concentrated into the concentration be equivalent to containing 1.4 ~ 1.8kg crude drug in often liter of extractum.
7. Chinese medicine preparation according to claim 3, is characterized in that, the amount of water described in step S3 is 10 ~ 20 times of crude drug total amount.
8. Chinese medicine preparation according to claim 3, is characterized in that, filters and refer to successively through ceramic membrane filter core and the ultrafiltration of 10Kda filter element described in step S3.
9. Chinese medicine preparation according to claim 3, is characterized in that, described in step S3, the degree of reverse osmosis concentration is: be concentrated into the concentration be equivalent to containing 1.8 ~ 3.6kg crude drug in often liter of concentrated solution.
10., according to the arbitrary described Chinese medicine preparation of claim 1 ~ 9, it is characterized in that, said preparation is oral formulations.
CN201511033759.0A 2015-12-31 2015-12-31 Traditional Chinese medicine preparation for treating fatty liver Pending CN105456575A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511033759.0A CN105456575A (en) 2015-12-31 2015-12-31 Traditional Chinese medicine preparation for treating fatty liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511033759.0A CN105456575A (en) 2015-12-31 2015-12-31 Traditional Chinese medicine preparation for treating fatty liver

Publications (1)

Publication Number Publication Date
CN105456575A true CN105456575A (en) 2016-04-06

Family

ID=55595032

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511033759.0A Pending CN105456575A (en) 2015-12-31 2015-12-31 Traditional Chinese medicine preparation for treating fatty liver

Country Status (1)

Country Link
CN (1) CN105456575A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101274044A (en) * 2008-05-15 2008-10-01 天科仁祥技术（北京）有限责任公司 Medicament for preventing and treating fatty liver and method of preparing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101274044A (en) * 2008-05-15 2008-10-01 天科仁祥技术（北京）有限责任公司 Medicament for preventing and treating fatty liver and method of preparing the same

Similar Documents

Publication Publication Date Title
CN100594928C (en) Curcuma extract and its prepn process, medicine composition and use
CN102139084B (en) Chinese medicinal composition for treating fatty liver and preparation method and application thereof
CN101461896B (en) Chinese medicinal composition assistant for reducing blood fat and preparation method thereof
CN104352624B (en) Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared
CN101700275A (en) Pharmaceutical preparation containing axillary choerospondias fruit and preparation method and application thereof
CN106535912B (en) Control pharmaceutical composition and its application of human body blood fat and body weight
CN104173922B (en) A kind of Chinese medicine for treating goiter
CN103610834A (en) Traditional Chinese medicine composition as well as preparation method and application thereof
CN115887568A (en) Traditional Chinese medicine composition for treating liver injury caused by lipid metabolism disorder and preparation method thereof
CN102000319B (en) Preparation method of stomach warming and soothing tablets
JP7340113B2 (en) Chinese herbal composition and its production method and use
CN105999058B (en) Bidens bipinnata lipid-lowering tablet
CN110237132B (en) Kidney-tonifying and lipid-lowering medicine, preparation method and application thereof
CN102488810B (en) Applications of huoxiangzhengqi soft capsule serving as medicinal preparations for treating cardiovascular and cerebrovascular diseases
CN105456575A (en) Traditional Chinese medicine preparation for treating fatty liver
CN105535866A (en) Medicine for treating hyperlipidemia and preparation method thereof
CN105726921A (en) Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood
CN105876236A (en) Feed additive for preventing and treating infectious rhinitis of chickens and preparation method thereof
CN100525804C (en) Chinese traditional medicine compound preparations having a function of slimming
CN100453073C (en) Compound radical lobelia dripping pill and its preparing method
TWI440465B (en) Herbal extract mixture for reducing blood lipid and a combination thereof
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN107638472A (en) A kind of Chinese medicine composition for treating nephrosis of quenching one&#39;s thirst and preparation method thereof
CN105641633A (en) Application of Chinese herbal medicine preparation in preparing medicine for treating obesity
CN116236553A (en) Traditional Chinese medicine composition with auxiliary blood lipid reducing function and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160406

RJ01 Rejection of invention patent application after publication